KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBITDA (2020 - 2025)

Recursion Pharmaceuticals' EBITDA history spans 6 years, with the latest figure at -$108.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 41.05% year-over-year to -$108.3 million; the TTM value through Dec 2025 reached -$648.1 million, down 38.33%, while the annual FY2025 figure was -$648.1 million, 35.31% down from the prior year.
  • EBITDA reached -$108.3 million in Q4 2025 per RXRX's latest filing, up from -$172.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$30.5 million in Q1 2021 to a low of -$191.4 million in Q1 2025.
  • Average EBITDA over 5 years is -$94.0 million, with a median of -$84.0 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 153.94% in 2021, then surged 41.05% in 2025.
  • A 5-year view of EBITDA shows it stood at -$65.0 million in 2021, then increased by 6.12% to -$61.0 million in 2022, then crashed by 62.23% to -$98.9 million in 2023, then crashed by 85.76% to -$183.8 million in 2024, then soared by 41.05% to -$108.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's EBITDA are -$108.3 million (Q4 2025), -$172.2 million (Q3 2025), and -$176.2 million (Q2 2025).